Steven Hendler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Steven Hendler has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Berkeley N. Limketkai
Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA 90095, USA
3 shared publications David Limsui
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
2 shared publicationsGrant E. Barber
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
2 shared publicationsMatthew S. Chang
Department of Gastroenterology, Kaiser Permanente-San Francisco, San Francisco, CA, USA
2 shared publicationsPhilip N. Okafor
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
2 shared publications- Aida Habtezion
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA
1 shared publication
Latest Publications
- 1 February 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 47, 70-77
The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial
- 1 February 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 47, 70-77
The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial
- 2 March 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 35 (5) , 897-903
Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide
Background Cytomegalovirus (CMV) infection may complicate ulcerative colitis (UC) or Crohn’s disease (CD) hospitalizations. Studies examining this relationship are often single-center examining short time periods. Aims To quantify the prevalence of CMV and its impact on outcomes among UC and CD hospitalizations over time using nationwide administrative databases. Methods The National Inpatient Sample and Nationwide Readmissions Database were analyzed to calculate CMV prevalence per 1000 UC and CD hospitalizations between 1998 and 2014. Univariable and multivariable logistic and linear regression were used to assess CMV’s association with outcomes. Separate analyses examined effects from the introduction of anti-TNF therapy in UC in 2005, CD anatomic extent, and Clostridioides difficile infection. Results Among UC, from 1998 to 2014, the prevalence of CMV infection rose from 1.4 to 6.3 per 1000 UC hospitalizations (p < 0.001), although this increase was not statistically significant for the years 2006 to 2014 (p = 0.07). Among CD, prevalence rose from 0.3 to 1.8 per 1000 CD hospitalizations (p < 0.001) from 1998 to 2014. CMV was independently associated with increased inpatient mortality (UC: odds ratio (OR) 2.3, 95% confidence interval (CI) 1.2–4.5; CD: OR 4.6, CI 1.5–13.7), colectomy in UC (OR 2.5, CI 1.9–3.3), and higher length of stay and costs. Conclusion CMV infection’s prevalence among UC and CD hospitalizations is rising over time, but may have slowed after 2005 in UC. CMV is independently associated with increased inpatient mortality, length of stay, and hospital charges in UC and CD and with colectomy in UC.
- 2 March 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 35 (5) , 897-903
Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide
Background Cytomegalovirus (CMV) infection may complicate ulcerative colitis (UC) or Crohn’s disease (CD) hospitalizations. Studies examining this relationship are often single-center examining short time periods. Aims To quantify the prevalence of CMV and its impact on outcomes among UC and CD hospitalizations over time using nationwide administrative databases. Methods The National Inpatient Sample and Nationwide Readmissions Database were analyzed to calculate CMV prevalence per 1000 UC and CD hospitalizations between 1998 and 2014. Univariable and multivariable logistic and linear regression were used to assess CMV’s association with outcomes. Separate analyses examined effects from the introduction of anti-TNF therapy in UC in 2005, CD anatomic extent, and Clostridioides difficile infection. Results Among UC, from 1998 to 2014, the prevalence of CMV infection rose from 1.4 to 6.3 per 1000 UC hospitalizations (p < 0.001), although this increase was not statistically significant for the years 2006 to 2014 (p = 0.07). Among CD, prevalence rose from 0.3 to 1.8 per 1000 CD hospitalizations (p < 0.001) from 1998 to 2014. CMV was independently associated with increased inpatient mortality (UC: odds ratio (OR) 2.3, 95% confidence interval (CI) 1.2–4.5; CD: OR 4.6, CI 1.5–13.7), colectomy in UC (OR 2.5, CI 1.9–3.3), and higher length of stay and costs. Conclusion CMV infection’s prevalence among UC and CD hospitalizations is rising over time, but may have slowed after 2005 in UC. CMV is independently associated with increased inpatient mortality, length of stay, and hospital charges in UC and CD and with colectomy in UC.
- 16 October 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (6) , 1661-1668
Reduction in Hospitalizations for Esophageal Reflux in a Decade with Minimal Increases in Other Functional and Motor Disorders
Functional and motility disorders (FMDs) are common conditions that cause significant morbidity and economic loss. A comprehensive analysis of these disorders and their impact has not been done in an inpatient setting.
- 16 October 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (6) , 1661-1668
Reduction in Hospitalizations for Esophageal Reflux in a Decade with Minimal Increases in Other Functional and Motor Disorders
Functional and motility disorders (FMDs) are common conditions that cause significant morbidity and economic loss. A comprehensive analysis of these disorders and their impact has not been done in an inpatient setting.
- 18 December 2018
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 34 (1) , 73-79
Fecal Microbiota Transplantation for the Critically Ill Patient
The gut microbiome has been implicated in a diversity of diseases, such as irritable bowel syndrome, inflammatory bowel disease, hepatic steatosis, metabolic syndrome, obesity, and anxiety. Current research also suggests the presence of a bidirectional relationship between the composition of the gut microbiome and critical illness. In the critical care setting, multiple factors (eg, use of antibiotics, aberrant nutrition, bloodstream infections, bowel ischemia, and abnormal bowel motility) strongly contribute to intestinal dysbiosis. Conversely, early studies have associated intestinal dysbiosis with worse clinical outcomes in the intensive care unit (ICU), such as infection, organ failure, and mortality. The possibility of intestinal dysbiosis influencing these clinical outcomes has prompted the question of whether microbiome manipulation strategies, such as fecal microbiota transplantation (FMT), may have a role in the management of critical illness. After a literature search of FMT used in the ICU for indications other than Clostridium difficile infections, we found 4 case reports that describe the use of FMT in 5 critically ill patients with systemic inflammatory responses and no clear source of infection. This review discusses the relationship between the gut microbiome and critical illness, early data on the use of FMT in critical care, and safety considerations of FMT in the critically ill and immunocompromised populations.
- 18 December 2018
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 34 (1) , 73-79
Fecal Microbiota Transplantation for the Critically Ill Patient
The gut microbiome has been implicated in a diversity of diseases, such as irritable bowel syndrome, inflammatory bowel disease, hepatic steatosis, metabolic syndrome, obesity, and anxiety. Current research also suggests the presence of a bidirectional relationship between the composition of the gut microbiome and critical illness. In the critical care setting, multiple factors (eg, use of antibiotics, aberrant nutrition, bloodstream infections, bowel ischemia, and abnormal bowel motility) strongly contribute to intestinal dysbiosis. Conversely, early studies have associated intestinal dysbiosis with worse clinical outcomes in the intensive care unit (ICU), such as infection, organ failure, and mortality. The possibility of intestinal dysbiosis influencing these clinical outcomes has prompted the question of whether microbiome manipulation strategies, such as fecal microbiota transplantation (FMT), may have a role in the management of critical illness. After a literature search of FMT used in the ICU for indications other than Clostridium difficile infections, we found 4 case reports that describe the use of FMT in 5 critically ill patients with systemic inflammatory responses and no clear source of infection. This review discusses the relationship between the gut microbiome and critical illness, early data on the use of FMT in critical care, and safety considerations of FMT in the critically ill and immunocompromised populations.